{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:45:20Z","timestamp":1774385120628,"version":"3.50.1"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:p>This cohort study calculates clinical trial sample sizes powered by visual pathway outcomes of acute optic neuritis in neuroprotection research.<\/jats:p>","DOI":"10.1001\/jamaneurol.2024.0462","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T15:00:43Z","timestamp":1711378843000},"page":"553","source":"Crossref","is-referenced-by-count":1,"title":["Visual Pathway Outcomes Based on Sample Size in Clinical Neuroprotection Research"],"prefix":"10.1001","volume":"81","author":[{"given":"Sebastian","family":"K\u00fcchlin","sequence":"first","affiliation":[{"name":"Eye Center, Medical Center\u2013University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Medical Center\u2013University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven P.","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Eye Center, Medical Center\u2013University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"M\u00e1rquez Neila","sequence":"additional","affiliation":[{"name":"ARTORG, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Department of Neurology, Maria Hilf Clinics M\u00f6nchengladbach, M\u00f6nchengladbach, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Hug","sequence":"additional","affiliation":[{"name":"Pharmacy, Medical Center\u2013University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf A.","family":"Lagr\u00e8ze","sequence":"additional","affiliation":[{"name":"Eye Center, Medical Center\u2013University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"Pt 2","key":"nld240001r1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/brain\/awr264","article-title":"Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis.","volume":"135","author":"Syc","year":"2012","journal-title":"Brain"},{"issue":"2","key":"nld240001r2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaneurol.2019.3283","article-title":"Using acute optic neuritis trials to assess neuroprotective and remyelinating therapies in multiple sclerosis.","volume":"77","author":"Andorr\u00e0","year":"2020","journal-title":"JAMA Neurol"},{"issue":"2","key":"nld240001r3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001126","article-title":"Leveraging visual outcome measures to advance therapy development in neuroimmunologic disorders.","volume":"9","author":"Graves","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"nld240001r4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1474-4422(21)00322-7","article-title":"Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.","volume":"20","author":"Lagr\u00e8ze","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"nld240001r5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.v77.3","article-title":"Dynamics of retinal injury after acute optic neuritis.","volume":"77","author":"Gabilondo","year":"2015","journal-title":"Ann Neurol"},{"issue":"10111","key":"nld240001r6","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2816801\/jamaneurology_kchlin_2024_ld_240001_1714578893.78706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T15:01:57Z","timestamp":1715612517000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2816801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.0462","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}